Two randomized clinical trials, DETECT III and Treat CTC, have been initiated recently to evaluate whether patients with persistent isolated tumor cells benefit from HER2 targeted therapy based on HER2 status of their MRD [47,48]. Here, ERBB2 is linked to neoplasm.